Free tool
Cell therapy stocks
We cover 5 companies grouped under the Cell therapy theme. The median market value in the group is $415.26M. Across the group, the median move over the past trading day is +1.60%. Price change over the past year runs from −23.0% to +156.7% across the middle 80 percent of the group, with a median of +15.7%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
5 of 86 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| SYNC.L | Syncona Limited | $923.83M | Small cap | +15.68% |
| 0JDK.L | Iovance Biotherapeutics, Inc. | $501.00M | Small cap | +248.46% |
| 0HX7.L | Adicet Bio, Inc. | $415.26M | Small cap | −24.75% |
| ALCLS.PA | Cellectis S.A. | $345.47M | Small cap | +19.05% |
| 0HIY.L | Atara Biotherapeutics, Inc. | $124.82M | Small cap | −20.36% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.